TETRA TECHNOLOGIES, INC. TO PARTICIPATE IN THE PIPER SANDLER 26TH ANNUAL ENERGY CONFERENCE Accessibility Statement Skip NavigationSPRING, Texas, March 4, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced that Brady Murphy, Chief Executive Officer; Elijio Serrano, Chief Financial Officer; and Kurt Hallead, VP of Investor Relations and Treasurer, will be hosting one-on-one meetings with institutional investors on March 17, 2026 during the Piper Sandler 26th Annual E ...

Financial Data and Key Metrics Changes - TETRA Technologies reported a record-setting year in 2025, with completion fluids and products revenue of $83.7 million, up 22% year-over-year, and adjusted EBITDA margins at 28.2% [23][24] - Free cash flow from the base business was $83 million for the year, exceeding the target of $50 million [26][27] - Cash on hand at the end of 2025 was $73 million, double the amount at the start of the year, with net debt reduced to $109 million from $143 million [29][30] Business Line Data and Key Metrics Changes - The Gulf of America Completion Fluids team achieved over 50% revenue growth in 2025 compared to 2024, driven by deepwater projects [6][7] - The global calcium chloride business set both revenue and adjusted EBITDA records, with tech-grade products for chip manufacturing growing by 144% in 2025 [8][9] - Water and flowback services revenue was flat compared to Q3, but strong activity was noted in Argentina, contributing to future growth [23] Market Data and Key Metrics Changes - The Gulf of America market saw a significant increase in completion activity in 2025, although a shift towards more drilling is expected in 2026 [18][40] - The overall deepwater market is projected to remain positive over the next 3 to 4 years, despite a decrease in floating deepwater rigs operating globally [9][40] Company Strategy and Development Direction - TETRA's ONE TETRA 2030 strategy focuses on expanding its market position in completion fluids, specialty chemicals, and water desalination [5][17] - Significant progress was made on the new bromine plant, with expectations to increase capacity to 75 million pounds of bromine annually by 2029 [10][11] - The company is exploring partnerships for magnesium production and evaluating lithium extraction technologies as future opportunities [12][13] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2025 due to reduced U.S. onshore activity and a volatile global economic environment but highlighted record financial achievements [5] - The outlook for 2026 includes incremental revenue growth driven by electrolyte business and major contract awards in Argentina, with expectations to double revenue compared to 2025 [17][19] - Management expressed confidence in maintaining adjusted EBITDA margins in the 25%-30% range for completion fluids despite increased costs for bromine [19][44] Other Important Information - Elijio Serrano, the CFO, announced his retirement effective at the end of March, with a planned transition to ensure continuity [21][22] - The company received a patent for its TETRA Oasis desalination solution, enhancing its competitive position in the market [14][15] Q&A Session Summary Question: Outlook for the deepwater market in 2026 - Management indicated a shift towards more drilling in 2026, with expectations for a cycle back to stronger completion activity in 2027 [40] Question: Margin progression for completion fluids - Pricing power remains strong, with expectations for adjusted EBITDA margins in the 25%-30% range, despite increased costs for bromine [44][78] Question: Timing for desalination projects - Management is hopeful for revenue from large-scale desalination projects in 2027, with ongoing discussions with multiple customers [58][91] Question: Bromine supply and pricing - The company is securing third-party bromine supply at higher prices, but expects to maintain margins through innovation and pricing power [77][78] Question: Impact of Venezuela on offshore business - Management views the situation in Venezuela positively for long-term oil field services, but does not expect significant short-term impacts [94]

Financial Data and Key Metrics Changes - TETRA Technologies reported a record-setting year in 2025, with completion fluids and products revenue of $83.7 million, up 22% year-over-year, and adjusted EBITDA margins at 28.2% [23][24] - Free cash flow from the base business was $83 million for the year, exceeding the target of $50 million [26][29] - The company ended 2025 with cash on hand of $73 million, double the amount at the beginning of the year, and reduced net debt from $143 million to $109 million [29][30] Business Line Data and Key Metrics Changes - The Gulf of America Completion Fluids team saw revenue increase over 50% in 2025 compared to 2024, driven by deepwater projects [6][7] - The global calcium chloride business set both revenue and adjusted EBITDA records, with tech-grade products for chip manufacturing growing by 144% in 2025 [8][9] - Water and flowback services revenue was flat at $63 million compared to the third quarter, but strong activity in Argentina was noted [23] Market Data and Key Metrics Changes - The company noted a 55% decrease in floating deepwater rigs operating globally compared to the 2014 peak, yet still achieved record financial performance [9] - The demand for bromine and electrolyte production is expected to increase, with the company securing third-party bromine supply to meet growing demand [19][78] Company Strategy and Development Direction - TETRA's ONE TETRA 2030 strategy focuses on expanding its market position in specialty chemicals, water desalination, and treatment [17] - Significant progress was made on a new bromine plant, with expectations to reach a capacity of 75 million pounds of bromine annually by 2029 [10][11] - The company is optimistic about partnerships for magnesium metal production and re-engaging with lithium extraction technology companies [12][13] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2025 due to reduced U.S. onshore activity and a volatile global economic environment but highlighted record financial achievements [5] - The outlook for 2026 includes modest growth driven by increased electrolyte business and major contract awards in Argentina, with expectations for a strong year in 2026 [17][18] - Management expects completion fluids and products adjusted EBITDA margins to be in the 25%-30% range for 2026, consistent with historical averages [19][44] Other Important Information - The company is transitioning leadership as CFO Elijio Serrano plans to retire, with Matt Sanderson taking over [21][22] - TETRA received a patent for its TETRA Oasis TDS end-to-end desalination solution, enhancing its competitive position in the market [14][15] Q&A Session Summary Question: Insights on the deepwater market for fluids in 2026 - Management indicated that while 2025 was a record year, 2026 is expected to see a shift towards more drilling and less completion activity, with a positive outlook for the deepwater market over the next few years [39][40] Question: Margin progression and pricing situation for deepwater fluids - Management confirmed strong pricing power in completion fluids due to innovation leadership, with expected margins in the 25%-30% range despite increased bromine costs [43][44] Question: Timing for desalination projects and commercial contracts - Management expressed optimism about finalizing commercial contracts for larger desalination plants, with potential revenue expected in 2027 [60][61] Question: Bromine supply and market demand - Management clarified that third-party bromine supply is being secured to meet demand, with no issues with the long-term contract, and pricing power is expected to help offset costs [78][79] Question: Long-term impact of changes in Venezuela on the offshore business - Management believes the changes in Venezuela will have a positive long-term impact on the oil field services market, though short-term effects are not expected to be significant [95]

TETRA Technologies (NYSE:TTI) Q4 2025 Earnings call February 26, 2026 10:30 AM ET Speaker7Hello, thank you for standing by. My name is Tiffany, I will be your conference operator today. At this time, I would like to welcome everyone to the TETRA Technologies, Inc. 4Q 2025 and full year 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during that time ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . COMMISSION FILE NUMBER 1-13455 TETRA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 74-2148293 (State or Other Jurisdiction ...

Exhibit 99.1 TETRA TECHNOLOGIES, INC. ANNOUNCES FOURTH-QUARTER AND STRONG FULL-YEAR 2025 RESULTS AND PROVIDES UPDATE ON STRATEGIC INITIATIVES Water & Flowback Services fourth quarter revenues were flat with the third quarter but down 4% year over year, materially less than the decline in U.S. frac activity, which was down 15% sequentially and down 24% from the fourth quarter of 2024 according to U.S. frac spread count data provided by Primary Vision as of December 31, 2025. While drilling and completions ac ...

TETRA TECHNOLOGIES, INC. ANNOUNCES FOURTH-QUARTER AND STRONG FULL-YEAR 2025 RESULTS AND PROVIDES UPDATE ON STRATEGIC INITIATIVES [Accessibility Statement] Skip NavigationSPRING, Texas, Feb. 25, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced financial results for the three and twelve months ended December 31, 2025.Fourth-Quarter 2025 Financial Highlights- Adjusted free cash flow was $3.1 million and base business adjusted free cash flow was exceptionally strong ...

Group 1 - The company is expected to release its next financial report for Q4 2025 and the full year in early 2026, with a focus on whether it can maintain its growth momentum [1] - The latest financial report for Q3 2025 shows revenue of $153 million and adjusted EBITDA of $25 million [1] Group 2 - The company has achieved a 92% water recovery rate in its desalination pilot project with EOG Resources in the Permian Basin, which could serve as a medium to long-term growth catalyst if scaled commercially [2] - The transition from pilot to large-scale commercial application will depend on customer investment decisions and regulatory approvals, with limited short-term profit contributions [2] Group 3 - The company's revenue is highly dependent on unconventional oil and gas activities in North America, and significant fluctuations in oil prices or operators cutting completion budgets could directly impact orders [3] - It is important to monitor U.S. energy policies, drilling activity data, and oil price trends for their effects on the business [3]

Core Viewpoint - The company TTI is expected to release its next financial report in early 2026, with a focus on maintaining its growth momentum in performance [1][2]. Financial Performance - The latest financial report for Q3 2025 showed revenue of $153 million and an adjusted EBITDA of $25 million, raising concerns about the ability to sustain growth in future reports [2]. Business Progress - The desalination pilot project with EOG Resources in the Permian Basin has achieved a 92% water recovery rate, which is crucial for transitioning the technology from pilot to large-scale commercial application, potentially serving as a medium to long-term growth catalyst [3]. Industry Policy and Environment - The company's revenue is highly dependent on unconventional oil and gas activities in North America. Significant fluctuations in oil prices or reductions in operators' completion budgets could directly impact orders. Monitoring U.S. energy policies, drilling activity data, and oil price trends is essential for understanding business impacts [4]. Institutional Perspectives - As of December 22, 2025, five participating institutions have given a "buy" recommendation, but there is a need to assess whether valuation levels align with performance growth. Any underperformance in future reports or business developments may lead to rating adjustments [5]. Future Development - While Oasis TDS has environmental and resource potential, large-scale implementation requires customer investment decisions and regulatory approvals, with limited short-term profit contributions. The stock often experiences low liquidity, which may amplify price volatility [6].

Core Viewpoint - Thiogenesis Therapeutics is advancing its nephropathic cystinosis program with a new investigator-initiated study for its lead product candidate TTI-0102, aimed at improving treatment adherence and patient quality of life [1][10]. Company Overview - Thiogenesis Therapeutics, Corp. is a clinical-stage biotechnology company focused on developing sulfur-based prodrugs for rare pediatric diseases, with operations based in San Diego, California [14]. - The company is publicly traded on the TSX Venture Exchange and OTCQX [14]. Product Development - TTI-0102 is a next-generation cysteamine-based prodrug designed to provide sustained cysteamine exposure with lower peak plasma concentrations, allowing for once-daily oral dosing [5][13]. - The product aims to address limitations of current cysteamine therapies, which include frequent dosing and gastrointestinal intolerance [4][10]. Clinical Study - The investigator-initiated study (IIS) will evaluate TTI-0102 in patients with nephropathic cystinosis, focusing on once-daily dosing, tolerability, and white blood cell (WBC) cystine control [2][10]. - Data from this study is expected to support dose optimization and inform the planned Phase 3 pivotal program [2][6]. Regulatory Pathway - Thiogenesis is preparing to scale up manufacturing for a newly patented salt formulation of TTI-0102, which is necessary for clinical material and stability testing [6]. - The company plans to initiate a Phase 3 pivotal, non-inferiority study comparing TTI-0102 to an approved cysteamine therapy under the FDA's 505(b)(2) regulatory pathway [7]. Market Opportunity - Nephropathic cystinosis affects an estimated 2,000–2,500 patients globally, representing a market opportunity exceeding $300 million [12]. - Current cysteamine therapies face significant challenges in tolerability and adherence, indicating a strong unmet medical need [12].